December 20th 2021
Shared insight on the role cardiovascular disease management plays in the prostate cancer treatment paradigm.
October 26th 2021
Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.
August 13th 2021
X. Long Zheng, MD, PhD, gives an overview of acquired thrombotic thrombocytopenic purpura and the treatment considerations for the disease.
August 5th 2021
Rheumatologist Ellen Ginzler, MD, MPH, and nephrologist German Hernandez, MD, FASN, FACP, explore the current treatment landscape of lupus nephritis and the managed care considerations of recent FDA approved therapies for the disease.
January 26th 2021
Key opinion leaders discuss the key differences and unmet needs in disease management for heart failure with preserved ejection fraction and heart failure with reduction ejection fraction.
January 25th 2021
Oncologists explore the opportunity of CAR T-cell therapy for the treatment of relapsed/refractory multiple myeloma.
January 18th 2021
A clinician and payer discuss the impact of chemotherapy-induced neutropenia on patients as well as the healthcare system, and discuss the latest in prophylactic treatment, especially during the COVID-19 pandemic.
January 14th 2021
Examining current treatment options for brain metastases in metastatic HER2+ breast cancer and assessing the clinical and economic burden.
December 4th 2020
The impact of the COVID-19 pandemic on managing HIV and strategies implemented to address challenges faced by providers.